Sutro Biopharma, Inc. (STRO): Operating Cash Flow
-$177.23M
Year ended 2025-12-31
-$145.17M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$177.23M | n/m | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | -$191.54M | n/m | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | -$111.62M | n/m | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $3.55M | n/m | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | -$81.68M | n/m | 2024-03-25, From 2021-01-01 |
| 2020-12-31 | -$67.80M | n/m | 2023-03-30, From 2020-01-01 |
| 2019-12-31 | -$65.02M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $12.68M | n/m | 2021-03-18, From 2018-01-01 |
| 2017-12-31 | -$37.07M | n/m | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | -$13.15M | n/a | 2019-04-01, From 2016-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$177.23M | n/m |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | -$103.88M | n/m |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | -$304.94M | n/m |
| Agenus Inc (AGEN) | 2025-12-31 | -$77.19M | n/m |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | -$50.94M | n/m |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | -$109.08M | n/m |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | -$22.80M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$46.36M | n/m |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | -$283.57M | n/m |
Compare STRO, IPSC, IBRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗